Supplementary table 1. Patient demographics and baseline/disease characteristics of all SLE without active LN clinical trials

Study name, NCT number	Treatment	Patients, n (%)	Age, years	Sex, female, n (%)	Baseline background therapy, n (%)	Primary trial length, weeks	Ref
Anifrolumab							
TULIP-1, NCT02446912	Anifrolumab 300mg vs 150mg vs placebo	T1 180 T2 93 C 184	T1 42.0±12.0 T2 40.8±12.0 C 41.0±12.3	T1 165 (92) T2 86 (92) C 171 (93)	T1 CS 150 (83); AM 124 (69); IM 85 (47) T2 CS 78 (84); AM 76 (82); IM 39 (42) C CS 153 (83); AM 134 (73); IM 94 (51)	52	[1]
TULIP-2, NCT02446899	Anifrolumab 300mg vs placebo	T 180 C 182	T 43.1±12.0 C 41.1±11.5	T 168 (93.3) C 170 (93.4)	T CS 141 (78); AM 119 (66); IM 88 (49) C CS 151 (83); AM 133 (73); IM 86 (47)	52	[2]
MUSE, NCT01438489	Anifrolumab 1000mg (T1) vs 300mg (T2) vs placebo	T1 104 T2 99 C 102	T1 40.8±11.6 T2 39.1±11.9 C 39.3±12.9	T1 99 (95.2) T2 93 (93.9) C 93 (91.2)	T1 CS 91 (88); AM 68 (65); IM 47 (45) T2 CS 79 (80); AM 76 (77); IM 53 (54) C CS 88 (86); AM 75 (74); IM 46 (45)	24	[3]
Belimumab							
BLISS-52, NCT00424476	Belimumab 10mg/kg vs 1mg/kg vs placebo	T1 290 T2 288 C 287	T1 35.4 (10.8) T2 35.0 (10.6) C 36.2 (11.8)	T1 280 (97) T2 271 (94) C 270 (94)	T1 CS 278 (96); AM 185 (64); IM 123 (42) T2 CS 276 (96); AM 195 (68); IM 120 (42) C CS 276 (96); AM 201 (70); IM 122 (43)	52	[4]
BLISS-76, NCT00410384	Belimumab 10mg/kg vs 1mg/kg vs placebo	T1 273 T2 271 C 275	T1 40.5±11.1 T2 40.0±11.4 C 40±11.9	T1 259 (94.9) T2 253 (93.4) C 252 (91.6)	T1 CS 200 (73); AM 168 (62); IM 148 (54) T2 CS 211 (78); AM 171 (63); IM 153 (57) C CS 212 (71); AM 180 (66); IM 154 (56)	52	[5]
BLISS-BELIEVE NCT03312907	Belimumab sc+ Rituximab (T1) vs Belimumab sc+ Standard Therapy (T2) vs Belimumab sc + Placebo (C)	T1 144 T2 76 C 72	T1 40.1 (11.45) T2 41.0 (12.75) C 40.6 (12.58)	T1 129 (89.6) T2 73 (96.1) C 66 (91.7)	NR	52	[6]
Study 113750, NCT01345253 (Asians)	Belimumab 10mg/kg vs placebo	T 451 C 226	T 32.3 (9.65) C 31.7 (9.18)	T 419 (92.9) C 210 (92.9)	T1 CS 443(98); AM 320 (71); IM 292 (65) C CS 223(99); AM 157 (70); IM 146 (65)	52	[7]
EMBRACE, NCT01632241 (Black Americans)	Belimumab 10mg/kg vs placebo	T 299 C 149	T 38.6±11.1 C 39.3±12.2	T 290 (97.0) C 144 (96.6)	T CS 246 (82); AM 237 (79); IM 167 (56) C CS 127(85); AM 124 (83); IM 88 (59)	52	[8]
BASE, NCT01705977	Belimumab 10mg/kg vs placebo	T 2001 C 2002	T 40.4 (12.75) C 40.8 (2.74)	T 1848 (92.4) C1853 (92.6)	NR	52	[9]
Study LBSL02, NCT00071487	Belimumab 10mg/kg (1T) vs 4mg/kg (2T) vs 1mg/kg (3T) vs placebo (C)	1T 111 2T 111 3T 114 C 113	T1 41.8±11.7 T2 42.6±10.7 T3 42.0±11.7 C 42.2±10.9	T1 105 (94.6) T2 105 (94.6) T3 107 (93.9) C 102 (90.3)	T1 CS 74 (67); AM 77 (69); IM 58 (52) T2 CS 73 (66); AM 72 (65); IM 58 (53) T3 CS 78 (68); AM 80 (70); IM 52 (46) C CS 82 (73); AM 84 (74); IM 55 (49)	52	[10]
BLISS-SC, NCT01484496	Belimumab 200mg sc vs placebo	T 248 C 108	T 34.6±10.96 C 34.6±10.38	T 236 (95.2) C 106 (98.1)	T CS 231 (93); AM 177 (71); IM 117 (47) C CS 99 (92); AM 68 (63); IM 59 (55)	52	[11]
Rituximab							
EXPLORER, NCT00137969	Rituximab 1000mg vs placebo	T 169 C 88	T 40.2±11.4 C 40.5±12.8	T 152 (89.9) C 82 (93.2)	T AZ 54 (32); M 47 (28); MMF 67 (40) C AZ 32 (36); M 24 (27); MMF 32 (36)	52	[12]

BILAG, British Isles Lupus Assessment Group; C, placebo control group; CS, corticosteroid; AM, antimalarials; IM, immunosuppressant agent; AZ, Azathioprin; M, Methotrexate; MMF, mycophenolate mofetil; NR, not reported; PGA, Physician Global Assessment score; T, treatment group. SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.

Supplementary table 2. Summary of any events during the treatment period in all SLE without active LN clinical trials

Study name, NCT number	Any adverse event	Serious adverse events	Herpes zoster	Upper respiratory tract infection	Nasopharyngitis	Bronchitis	Urinary tract infection	Influenza	Ref
Anifrolumab									
TULIP-1, NCT02446912	T1 169 (89) T2 79 (85) C 144 (78)	T1 25 (14) T2 10 (11) C 30 (16)	T1 10 (6) T2 5 (5) C 3 (2)	T1 22 (12) T2 16 (17) C 18 (10)	T1 36 (20) T2 14 (15) C 22 (12)	T1 16 (9) T2 7 (8) C 10 (5)	T1 22 (12) T2 9 (10) C 27 (15)	T1 2 (1) T2 1 (1) C 2 (1)	[1]
TULIP-2 NCT02446899	T 159 (88.3) C 153 (84.1)	T 15 (8.3) C 31 (17.0)	T 13 (7.2) C 2 (1.1)	T 39 (21.7) C 18 (9.9)	T 28 (15.6) C 20 (11.0)	T 22 (12.2) C 7 (3.8)	T 20 (11.1) C 25 (13.7)	T 4 (2.2) C 6 (3.3)	[2]
MUSE, NCT01438489	T1 90 (85.7) T2 84 (84.8) C 78 (77.2)	T1 18 (17.1) T2 16 (16.2) C 19 (18.8)	T1 10 (9.5) T2 5 (5.1) C 2 (2.0)	T1 11 (10.5) T2 13 (13.1) C 10 (9.9)	T1 12 (11.4) T2 12 (12.1) C 4 (4.0)	T1 9 (8.6) T2 7 (7.1) C 4 (4.0)	T1 7 (6.7) T2 15 (15.2) C 11 (10.9)	T1 8 (7.6) T2 6 (6.1) C 2 (2.0)	[3]
Belimumab									
BLISS-52, NCT00424476	T1 266 (92) T2 264 (92) C 263 (92)	T1 41 (14) T2 47 (16) C 36 (13)	NR NR NR	T1 36 (12) T2 41 (14) C 47 (16)	T1 20 (7) T2 30 (10) C 23 (8)	NR NR NR	T1 26 (9) T2 30(9) C 25 (9)	T1 33 (11) T2 22 (8) C 25 (9)	[4]
BLISS-76, NCT00410384	T1 253 (92.7) T2 253 (93.4) C 253 (92.0)	T1 61 (22.3) T2 63 (23.2) C 54 (19.6)	NR NR NR	T1 54 (19.8) T2 53 (19.6) C 58 (21.1)	T1 43 (15.8) T2 29 (10.7) C 24 (8.7)	T1 32 (11.7) T2 19 (7.0) C 21 (7.6)	T1 44 (16.1) T2 50 (18.5) C 43 (15.6)	NR NR NR	[5]
BLISS-BELIEVE NCT03312907	T1 141 (97.9) T2 68 (89.5) C 58 (80.5)	T1 32 (22.2) T2 15 (19.7) C 10 (13.9)	NR NR NR	T1 31 (21.5) T2 12 (15.8) C 6 (8.3)	T1 32 (22.2) T2 18 (23.7) C 13 (18.1)	T1 10 (6.9) T2 7 (9.2) C 6 (8.3)	T1 27 (18.8) T2 27 (35.5) C 16 (22.2)	T1 4 (2.8) T2 4 (5.3) C 12 (16.7)	[6]
Study 113750, NCT01345253 (Asians)	T 352 (74.9) C 178 (75.7)	T 58 (2.3) C 43 (18.3)	T 29 (6.2) C 12 (5.1)	T 65 (13.8) C 39 (16.6)	T 56 (11.9) C 26 (11.1)	NR NR	T 20 (4.3) C 2 (0.9)	NR NR	[7]
EMBRACE, NCT01632241 (Black Americans)	T 277 (83.7) C 144 (87.3)	T 36 (10.9) C 31 (18.8)	NR NR	T 58 (17.5) C 20 (12.1)	NR NR	NR NR	T 57 (17.2) C 25 (15.1)	T 35 (10.6) C 23 (13.9)	[8]
BASE, NCT01705977	T 242 (12.09) C 256 (12.79)	T233 (11.64) C241 (12.04)	T17 (0.85) C31 (1.55)	NR NR	NR NR	NR NR	NR NR	NR NR	[9]
Study LBSL02, NCT00071487	T1 108 (97.3) T2 107 (96.4) T3 111 (97.4) C 110 (97.3)	T1 18 (16.2) T2 15 (13.5) T3 21 (18.4) C 22 (19.5)	NR NR NR NR	T1 29 (26.1) T2 36 (32.4) T3 36 (31.6) C 33 (29.2)	NR NR NR NR	NR NR NR NR	T1 20 (18.0) T2 19 (17.1) T3 16 (14.0) C 18 (15.9)	NR NR NR NR	[10]
BLISS-SC, NCT01484496	T 194 (78.2) C 88 (81.5)	T 33 (13.3) C25 (23.1)	T 7 (2.8) C 7 (6.5)	T 79 (31.9) C 38 (35.2)	T 38 (15.3) C 22 (20.4)	NR NR	T 41 (16.5) C 19 (17.6)	NR NR	[11]
Rituximab									
EXPLORER, NCT00137969	T 164 (97) C 85 (97)	T 72 (42.6) C 32 (36.4)	T 18 (10.7) C 4 (4.5)	T 54 (32) C 32 (36.4)	T 17 (10.1) C 5 (5.7)	T 28 (16.6) C 13 (14.8)	T 48 (28.4) C 29 (33.0)	T 9 (5.3) C 6 (6.8)	[12]

C, placebo control group; NR, not reported; T, treatment group.

Supplementary table 3. Patient demographics and baseline/disease characteristics of all active LN clinical trials

Study name, NCT number	Treatment	Patients, n (%)	Age, years	Sex, female, n (%)	Baseline background therapy, n (%)	Primary trial length, weeks	Ref.
Anifrolumab							
TULIP-LN, NCT02547922	Anifrolumab BR (300mg) vs IR (900mg for the first 3 doses, then 300mg) vs placebo	BR 45 IR 51 C 49	BR 34.0 IR 35.0 C 32.0	BR 37 (82.2) IR 45 (88.2) C 38 (77.6)	BR CS 43 (96); AM 31 (69); MMF 36 (80) IR CS 51 (100); AM 26 (51); MMF 36 (71) C CS 48 (98); AM 35 (71); MMF 33 (67)	52	[13]
Belimumab							
BLISS-LN, NCT01639339	Belilumab 10mg/kg vs placebo	T 223 C 223	T 33.7±10.7 C 33.1± 10.6	T 197 (88) C 196 (88)	T AM 166 (74); ACE-I/ARB 147 (66) C AM 154 (69); ACE-I/ARB 150 (67)	104	[14]
Rituximab							
LUNAR, NCT00282347	Rituximab 1000mg vs placebo	T 72 C 72	T 31.8±9.6 C 29.4±9.3	T 63 (87.5) C 67 (93.1)	MMF 72 (100)	52	[15]
Calibrate NCT02260934	Rituximab + Cyclophosmadie + Belimumab (T) vs Rituximab + Cyclophosmaide (C)	T 21 C 22	T 34.5 (9.1) C 32.3 (11.4)	T 19 (90.5) C 18 (81.8)	All patients were treated with either CYC or MMF	48	[16]

BILAG, British Isles Lupus Assessment Group; C, placebo control group; LN, lupus nephritis; NR, not reported; CS, corticosteroid; AM, antimalarials; CYC, cyclophosphamide; MMF, mycophenolate mofetil; ACE-I, ACE inhibitor; ARB, angiotensin-receptor blocker

Supplementary table 4. Summary of any events during the treatment period in all active LN clinical trials

Study name, NCT number	Any adverse event	Serious adverse events	Herpes zoster	Upper respiratory tract infection	Nasopharyngitis	Bronchitis	Urinary tract infection	Influenza	Ref.
Anifrolumab									
TULIP-LN, NCT02547922	BR 43 (95.6) IR 47 (92.2) C 44 (89.8)	BR 10 (22.2) IR 9 (17.6) C 8 (16.3)	BR 9 (20.0) IR 7 (13.7) C 4 (8.2)	BR 8 (17.8) IR 7 (13.7) C 8 (16.3)	BR 6 (13.3) IR 9 (17.6) C 9 (18.4)	BR 4 (8.9) IR 7 (13.7) C 6 (12.2)	BR 10 (22.2) IR 6 (11.8) C 5 (10.2)	BR 2 (4.4) IR 3 (5.9) C 1 (2.0)	[13]
Belimumab									
BLISS-LN, NCT01639339	T 214 (96) C 211 (94)	T 58 (26) C 67 (30)	T 13 (6) C 10 (4)	T 26 (12) C 24 (11)	T 8 (4) C 8 (4)	T 11 (5) C 10 (4)	T 15 (7) C 13 (6)	NR NR	[14]
Rituximab									
LUNAR, NCT00282347	T 72 (98.6) C 68 (95.8)	T 24 (32.9) C 29 (40.8)	T 11 (15.1) C 9 (12.7)	T 21 (28.8) C 23 (32.4)	NR NR	NR NR	T 17 (23.3) C 20 (28.2)	NR NR	[15]
Calibrate NCT02260934	T 21 (100.0) C 22 (100.0)	T 4 (19.1) C 6 (27.3)	T 3 (14.3) C 0	T 4 (19.0) C 6 (27.3)	T 3 (14.3) C 0	NR NR	T 2 (9.5) C 7 (31.2)	NR NR	[16]

BR, basic regimen 300mg Anifrolumab; C, placebo control group; IR, intensified regime 900mg for the first 3 doses, then 300mg; NR, not reported; MMF, mycophenolate mofetil; T, treatment group.

Supplementary table 5. Relative risk ratio of infectious complications in SLE without and with active LN clinical trials

Trial name	Herpes zoster	Upper respiratory tract infection	Nasopharyngitis	Nonopportunistic infection	Bronchitis	Urinary tract infection	Influenza
Non-renal SLE							
TULIP-1, TULIP-2, MUSE	4,77	1,48	1,98	1,25	2,39	0,74	1,82
BLISS-52, BLISS-76, LBSL02, Study 113750, EMBRACE, BASE	0,88	0,97	1,25	NR	1,54	1,82	0,99
EXPLORER	2,08	0,88	1,77	NR	1,21	0,96	0,78
Proliferative LN							
TULIP-LN	2,04	0,96	0,85	0,16	0,94	1,64	4,15
BLISS-LN	1,12	1,09	1,13	NR	0,95	1,16	1,00
LUNAR, CALIBRATE	0,67	0,87	0,39	NR	1,46	1,04	0,73

LN, lupus nephritis; NR, not reported; SLE, systemic lupus erythematosus.

Supplementary table 6. Odds ratios of infectious complications in SLE without and with active LN clinical trials

	OR of non-renal SLE trials (drug vs placebo) (95% CI)	OR of proliferative LN trials (drug vs placebo) (95% CI)	OR of placebo (LN vs SLE trials) (95% CI)	OR of biological drug (LN vs SLE trials) (95% CI)
TULIP-1, TULIP-2, MUSE, TULIP-LN				
Herpes zoster	5.49 (0.92 - 32.85)	2.8 (1.18 – 6.66, p = 0.018)	5.17 (0.97 – 27.6)	3.05 (1.26 – 7.42, p = 0.018)
Upper respiratory tract infection	1.57 (0.66 – 3.69)	0.95 (0.45 – 2.02)	1.77 (0.76 – 4.1)	1.07 (0.49 – 2.32)
Nasopharyngitis	1.88 (0.79 – 4.49)	0.82 (0.39 – 1.72)	2.28 (0.97 – 5.34)	0.99 (0.46 – 2.13)
Bronchitis	2.47 (0.77 - 7.96)	0.94 (0.4 – 2.21)	3.12 (1 – 9.74)	1.18 (0.48 – 2.89)
Nonopportunistic infection	1.26 (0.33 – 4.85)	0.16 (0.02 – 1.31)	1.56 (0.43 – 5.68)	0.19 (0.02 – 1.67)
Urinary tract infection	0.73 (0.3 – 1.74)	1.77 (0.77 – 4.06)	0.75 (0.31 – 1.78)	1.82 (0.79 – 4.21)
Influenza	1.74 (0.31 – 9.77)	4.44 (0.92 – 21.32)	0.95 (0.13 – 6.73)	2.42 (0.68 – 8.63)
BLISS-76, BLISS-52, LBSL02, Study 113750, EMBRACE, BASE, BLISS-LN				
Herpes zoster	1.06 (0.23 – 4.94)	1.13 (0.41 – 3.14)	2.39 (0.64 – 8.93)	2.53 (0.71 – 9.05)
Upper respiratory tract infection	0.93 (0.45 – 1.89)	1.15 (0.64 – 2.06)	2.1 (1.1 – 4.03, p = 0.02)	2.61 (1.36 – 5.02, p = 0.005)
Nasopharyngitis	1.27 (0.51 – 3.16)	1.15 (0.53 – 2.52)	1.61 (0.67 – 3.89)	1.46 (0.65 – 3.31)
Bronchitis	1.61 (0.62 – 4.2)	0.94 (0.34 – 2.58)	1.2 (0.43 – 3.33)	0.66 (0.26 – 1.7)
Nonopportunistic infection	NR	NR	NR	NR
Urinary tract infection	1.16 (0.5 – 2.73)	1.20 (0.58 – 2.48)	1.55 (0.69 – 3.5)	1.64 (0.76 – 3.53)
Influenza	0.94 (0.39 – 2.26)	1.00 (0.02 – 62.88)	0.03 (0 – 0.7)	0.04 (0 – 0.75)
EXPLORER, LUNAR, CALIBRATE				
Herpes zoster	2.19 (0.69 – 6.96)	0.64 (0.24 – 1.69)	2.66 (0.86 – 8.22)	0.78 (0.29 – 2.12)
Upper respiratory tract infection	0.82 (0.46 – 1.48)	0.81 (0.44 – 1.49)	0.84 (0.47 – 1.5)	0.83 (0.45 – 1.52)
Nasopharyngitis	1.86 (0.64 – 5.41)	0.37 (0.09 – 1.55)	1.26 (0.4 – 3.94)	0.25 (0.06 – 0.99)
Bronchitis	1.26 (0.58 – 2.74)	1.50 (0.49 – 4.56)	0.38 (0.14 – 1.05)	0.45 (0.19 – 1.1)
Nonopportunistic infection	NR	NR	NR	NR
Urinary tract infection	0.95 (0.51 – 1.74)	1.05 (0.57 – 1.94)	0.94 (0.51 – 1.73)	1.04 (0.56 – 1.92)
Influenza	0.77 (0.24 – 2.48)	0.72 (0.2 – 2.64)	0.82 (0.26 – 2.58)	0.76 (0.2 – 2.84)

CI, confidence interval; LN, lupus nephritis; NR, not reported; OR, odds ratio; SLE, systemic lupus erythematosus.

References

1. Furie R.A., Morand, E.F., Bruce, I.N., Manzi, S., Kalunian, K.C., Vital, E.M., Ford, T.L., Gupta, R., Hiepe, F., Santiago, M., Brohawn, P.Z., Berglind, A., Tummala, R., *Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.* The Lancet Rheumatology, 2019. **1**(4): p. E208-E219.
2. Morand E.F., Furie R., Tanaka Y., Bruce I.N., Askanase A.D., Richez C., Bae S.C., Brohawn P.Z., Pineda L., Berglind A., Tummala R., and Investigators T.-T., *Trial of Anifrolumab in Active Systemic Lupus Erythematosus.* N Engl J Med, 2020. **382**(3): p. 211-221.
3. Furie R., Khamashta M., Merrill J.T., Werth V.P., Kalunian K., Brohawn P., Illei G.G., Drappa J., Wang L., Yoo S., and Investigators C.D.S., *Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.* Arthritis Rheumatol, 2017. **69**(2): p. 376-386.
4. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Li E.K., Thomas M., Kim H.Y., Leon M.G., Tanasescu C., Nasonov E., Lan J.L., Pineda L., Zhong Z.J., Freimuth W., Petri M.A., and Group B.-S., *Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.* Lancet, 2011. **377**(9767): p. 721-31.
5. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., Stohl W., Ginzler E.M., Hough D.R., Zhong Z.J., Freimuth W., van Vollenhoven R.F., and Group B.-S., *A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.* Arthritis Rheum, 2011. **63**(12): p. 3918-30.
6. Teng Y.K.O., Bruce I.N., Diamond B., Furie R.A., van Vollenhoven R.F., Gordon D., Groark J., Henderson R.B., Oldham M., and Tak P.P., *Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.* BMJ Open, 2019. **9**(3): p. e025687.
7. Zhang F., Bae S.C., Bass D., Chu M., Egginton S., Gordon D., Roth D.A., Zheng J., and Tanaka Y., *A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.* Ann Rheum Dis, 2018. **77**(3): p. 355-363.
8. Ginzler E., Guedes Barbosa L.S., D'Cruz D., Furie R., Maksimowicz-McKinnon K., Oates J., Santiago M.B., Saxena A., Sheikh S., Bass D.L., Burriss S.W., Gilbride J.A., Groark J.G., Miller M., Pierce A., Roth D.A., and Ji B., *Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.* Arthritis Rheumatol, 2022. **74**(1): p. 112-123.
9. Sheikh S.Z., SCheinberg, M.A., Wei, J.C.C., Tegzova, D., Stohl, W., Acayaba de Toledo, R., Mucenic, T., Abello Banfi, M.R., Maksimowicz-McKinnon, K., Abud-Mendoza, C., Navarra, S., Garcia, M., Garcia-De- La Torre, I., Ros, J.O., Levy, R.A., et. al., *Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.* The Lancet Rheumatology, 2020. **3**(2): p. E122-E130.
10. Wallace D.J., Stohl W., Furie R.A., Lisse J.R., McKay J.D., Merrill J.T., Petri M.A., Ginzler E.M., Chatham W.W., McCune W.J., Fernandez V., Chevrier M.R., Zhong Z.J., and Freimuth W.W., *A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.* Arthritis Rheum, 2009. **61**(9): p. 1168-78.
11. Doria A., Stohl W., Schwarting A., Okada M., Scheinberg M., van Vollenhoven R., Hammer A.E., Groark J., Bass D., Fox N.L., Roth D., and Gordon D., *Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.* Arthritis Rheumatol, 2018. **70**(8): p. 1256-1264.
12. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., Utset T.O., Gordon C., Isenberg D.A., Hsieh H.J., Zhang D., and Brunetta P.G., *Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.* Arthritis Rheum, 2010. **62**(1): p. 222-33.
13. Jayne D., Rovin B., Mysler E.F., Furie R.A., Houssiau F.A., Trasieva T., Knagenhjelm J., Schwetje E., Chia Y.L., Tummala R., and Lindholm C., *Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.* Ann Rheum Dis, 2022. **81**(4): p. 496-506.

14. Furie R., Rovin B.H., Houssiau F., Malvar A., Teng Y.K.O., Contreras G., Amoura Z., Yu X., Mok C.C., Santiago M.B., Saxena A., Green Y., Ji B., Kleoudis C., Burriss S.W., Barnett C., and Roth D.A., *Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.* N Engl J Med, 2020. **383**(12): p. 1117-1128.
15. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., Maciuca R., Zhang D., Garg J.P., Brunetta P., Appel G., and Group L.I., *Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.* Arthritis Rheum, 2012. **64**(4): p. 1215-26.
16. Atisha-Fregoso Y., Malkiel S., Harris K.M., Byron M., Ding L., Kanaparthi S., Barry W.T., Gao W., Ryker K., Tosta P., Askanase A.D., Boackle S.A., Chatham W.W., Kamen D.L., Karp D.R., Kirou K.A., Sam Lim S., Marder B., McMahon M., Parikh S.V., Pendergraft W.F., 3rd, Podoll A.S., Saxena A., Wofsy D., Diamond B., Smilek D.E., Aranow C., and Dall'Era M., *Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.* Arthritis Rheumatol, 2021. **73**(1): p. 121-131.